{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:32:12Z","timestamp":1768469532717,"version":"3.49.0"},"reference-count":10,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Psoriasis and hidradenitis suppurativa are inflammatory dermatoses that have been associated with arthritis, metabolic syndrome, obesity, and smoking. They share common pathogenic mechanisms such as elevated levels of several proinflammatory cytokines including tumor necrosis factor (TNF), interleukin-17A, and impaired Notch pathway. Thus, treatments for both diseases are sometimes overlapping. Biological therapy such as adalimumab is effective for patients with hidradenitis suppurativa and psoriasis. Adalimumab is a monoclonal antibody that binds to TNF and inhibits the cytokine interaction with the TNF receptors, thus inhibiting the inflammatory cascade. Currently, data are lacking on the treatment for co-occurrence of psoriasis and hidradenitis suppurativa. This case series describes three patients with a diagnosis of concomitant psoriasis and hidradenitis suppurativa. In these cases, after 12 weeks of treatment with adalimumab 40 mg every other week, the average Psoriasis Area Severity Index score reduced from 21.4 to 2.9 for psoriasis, Hidradenitis Suppurativa-Physician\u2019s Global Assessment from 3.3 to 0.7, and pain Visual Analog Scale for hidradenitis suppurativa from 4.6 to 2. The results suggest that adalimumab is a treatment of choice for patients with concomitant hidradenitis suppurativa and psoriasis.<\/jats:p>","DOI":"10.4103\/ijdvl.ijdvl_455_18","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:32:20Z","timestamp":1565159540000},"page":"223-226","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series"],"prefix":"10.25259","volume":"87","author":[{"given":"Chi-Feng","family":"Yen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou,"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou,"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: A systematic review and meta-analysis","volume":"170","author":"Armstrong","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-2","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: An update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.15665","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017","volume":"177","author":"Smith","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jaad.2015.06.050","article-title":"Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): Experience of a tertiary medical center","volume":"73","author":"Patel","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/jamadermatol.2017.0432","article-title":"Interventions for hidradenitis suppurativa: Updated summary of an original cochrane review","volume":"153","author":"Ingram","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2133.2010.10034.x","article-title":"Hidradenitis suppurativa\/acne inversa: Bilocated epithelial hyperplasia with very different sequelae","volume":"164","author":"von Laffert","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-8","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1365-2133.1990.tb06264.x","article-title":"Hidradenitis suppurativa: A disease of follicular epithelium, rather than apocrine glands","volume":"122","author":"Yu","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00403-015-1594-7","article-title":"Biological therapy induces expression changes in Notch pathway in psoriasis","volume":"307","author":"Skarmoutsou","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.4103\/ijdvl.IJDVL_455_18\/ref-10","first-page":"1192","article-title":"Adalimumab treatment in women with moderate-to-severe hidradenitis suppurativa from the placebo-controlled portion of a phase 2, randomized, double-blind study","volume":"15","author":"Gottlieb","year":"2016","journal-title":"J Drugs Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/concomitant-psoriasis-and-hidradenitis-suppurativa-responsive-to-adalimumab-therapy-a-case-series\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/concomitant-psoriasis-and-hidradenitis-suppurativa-responsive-to-adalimumab-therapy-a-case-series\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T12:58:19Z","timestamp":1616504299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/concomitant-psoriasis-and-hidradenitis-suppurativa-responsive-to-adalimumab-therapy-a-case-series\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":10,"alternative-id":["10.4103\/ijdvl.IJDVL_455_18"],"URL":"https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_455_18","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"article-number":"223"}}